Xencor (XNCR) Announces Proposed Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/5/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- LCI Industries names interim CEO as Jason Lippert retires
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
Xencor Announces Proposed Public Offering of Common Stock
September 10, 2024 4:01 PM EDTPASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (Xencor) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has commenced an underwritten public offering of shares of its common stock, or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock. Xencor also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock (including shares of common stock underlying... More
